Phaseline

Targets › PDPN

PDPN (Podoplanin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.

Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation. (UniProt, Q86YL7)

Open in Phaseline: the race on PDPN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityEnvolizumab
Anti-podoplanin monoclonal antibody
PDPNPhase 2Head and Neck CancerSep 2027

Conditions

Head and Neck Cancer (1)

Modalities

antibody (1)

Companies

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.